Axiogenesis Secures Major Funding for its Expansion Course

COLOGNE, Germany, May 3, 2016 /PRNewswire/ — Axiogenesis has acquired a major investment from Sino-German High-Tech Fund to further expand product development, strengthen its disease modeling capabilities and increase market presence.

Sino-German High-Tech Fund (SGHF) is an investment fund jointly supported by Donghai Securities from China and High-Tech Gründerfonds from Germany. Its initiative signing ceremony was chaired by the German Chancellor Angela Merkel and the Chinese Prime Minister Li Keqiang in 2015. Up to 300 million Euro are to be invested in German high-tech companies over the next five years through SGHF, which focuses on high-end manufacturing, renewable energy, bio-technology, TMT and healthcare sectors, etc. With its capital and industry resources, SGHF will strongly support German companies’ market entry and expansion in China as well as their globalization strategies.

For the complete press release, click here (English) or here (German).


Axiogenesis US Symposium: "iPSC-Derived Cells & Assays Come of Age"


Learn how experts in the pharmaceutical industry and leading academic institutions are using Axiogenesis' cells and assays in drug discovery, safety/toxicology screening, and bioengeneering. Understand current approaches to establish and define standards for these cellular models. Get insights in case studies of iPS cells in drug development decision-making and biomedical research

For more details and the preliminary agenda please visit here


Recording of CHI's Webinar "Humanizing Early Drug Discovery and Preclinical Safety Testing with Physiological iPS Cell Models"  is online available now

Webinar Description:

Learn how human cardiac cells, derived from induced pluripotent stem cells (iPSC), are playing a rapidly increasing role in in vitro drug discovery & development assays in the pharmaceutical industry. From high-throughput screening (HTS) to toxicology testing, human cardiac cells can be applied in pure 2D cultures for desired controls as well as 3D co-culture systems for physiological relevance. Whether you are screening for new drug targets, or investigating drug effects on electrophysiology, contractility, or cardiac-specific toxicity, this seminar will provide insights for your own research.

Full length recording of the webinar available here

For more details please visit here


Cor.4U have electrophysiological parameters approaching adult human tissue

Axiogenesis Cor.4U human cardiomyocytes, serving as a human cellular model in a recent late stage pre-clinical safety study, demonstrated electrophysiological parameters approaching adult human tissue. The use of these Cor.4U cardiomyocytes was “consistent with the emphasis on (Multiple Ion Channel Effects) MICE of the CiPA assay”. The experimental paradigm presented by this study will be amodel for future drug safety screening efforts. 

For more details read the full article here


Nattermannallee 1, Bldg S20
50829 Cologne
Germany – (Map)

600 W Germantown Pike, Suite 110
Plymouth Meeting, PA 19462
USA – (Map)




Twitter:  |   LinkedIn:  |   Newsletter:  Subscribe Axiogenesis Newsletter


Phone (Main)
+49 221 99 88 18-0

Phone (US)
+1 844-511-6959

Fax + 49 221 99 88 18-10